Aurobindo Pharma Ltd
NSE:AUROPHARMA

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Watchlist
Price: 1 262.45 INR 0.65% Market Closed
Market Cap: 733.2B INR
Have any thoughts about
Aurobindo Pharma Ltd?
Write Note

Aurobindo Pharma Ltd
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aurobindo Pharma Ltd
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Net Income
â‚ą43.8B
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Net Income
â‚ą72.3B
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Net Income
â‚ą63.3B
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Net Income
â‚ą128.4B
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Net Income
â‚ą25.8B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Net Income
â‚ą24B
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aurobindo Pharma Ltd
Glance View

Market Cap
739.7B INR
Industry
Pharmaceuticals

Aurobindo Pharma Ltd., founded in 1986 by P.V. Ramprasad Reddy and K. Nityananda Reddy, began its journey in the bustling pharmaceutical landscape of Hyderabad, India. Initially starting as a provider of semi-synthetic penicillin, the company gradually diversified its product portfolio across major therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, and anti-diabetics, among others. With an entrepreneurial vision, Aurobindo leveraged vertical integration to optimize costs and operations—manufacturing everything from raw active pharmaceutical ingredients (APIs) to finished dosage formulations. This strategic approach not only reinforced its cost-leadership position but also enabled the company to meet stringent regulatory requirements in global markets, providing them a competitive edge. In its quest for expansion, Aurobindo penetrated international markets, including the United States and Europe, through acquisitions and strategic alliances, expanding its manufacturing capabilities and distribution networks. The company generates its revenue primarily through the sale of generic pharmaceuticals, which are manufactured in their state-of-the-art facilities and sold worldwide. Aurobindo's robust research and development (R&D) investments have further fueled its growth by enabling the company to introduce new and complex product lines, including biosimilars and specialty generics. This blend of strategic foresight, operational excellence, and commitment to innovation is what propels Aurobindo Pharma's ongoing narrative in the global pharmaceutical industry.

AUROPHARMA Intrinsic Value
1 134.89 INR
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Aurobindo Pharma Ltd's Net Income?
Net Income
43.8B INR

Based on the financial report for Jun 30, 2024, Aurobindo Pharma Ltd's Net Income amounts to 43.8B INR.

What is Aurobindo Pharma Ltd's Net Income growth rate?
Net Income CAGR 3Y
-16%

Over the last year, the Net Income growth was 68%. The average annual Net Income growth rates for Aurobindo Pharma Ltd have been -16% over the past three years .

Back to Top